Related Experiment Video
Updated: Jul 6, 2026
10:03
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
Progressive supranuclear palsy: a current review
Michael Lubarsky1, Jorge L Juncos
1Emory University School of Medicine, Atlanta, GA 30329, USA.
The Neurologist
|March 12, 2008
Summary
Progressive supranuclear palsy (PSP) is an under-recognized neurological disorder. Earlier detection through recognizing atypical presentations and improved imaging can reduce morbidity and enhance quality of life.
Area of Science:
- Neurology
- Neurodegenerative Disorders
Background:
- Progressive supranuclear palsy (PSP) is the second most common cause of parkinsonism, often misdiagnosed due to nonclassic presentations.
- Neurologists recognize classic PSP by down gaze palsy, rigidity, and imbalance, but proficiency in treating and identifying atypical forms is limited.
Purpose of the Study:
- To aid clinicians in earlier identification of Progressive supranuclear palsy (PSP).
- To deepen understanding of PSP pathophysiology.
- To guide a focused, symptom-based treatment approach for PSP.
Main Methods:
- Literature review of 82 peer-reviewed articles on PSP and related neurodegenerative disorders.
- Analysis of clinical, neuroimaging, pharmacologic, and molecular research.
Main Results:
- PSP involves multilevel neuraxis, distinguishing it from Parkinson's disease (PD).
- Advances in recognizing atypical presentations, neurobehavioral signs, and imaging aid earlier PSP detection.
- Surgical interventions for PSP have not been effective.
Conclusions:
- Earlier PSP detection can reduce morbidity by anticipating falls and minimizing unnecessary procedures.
- Targeted symptomatic treatments, including medications and therapies, can improve quality of life.
- Increased clinical awareness of atypical PSP presentations is crucial for timely diagnosis and management.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...